CN109476634A - 喹唑啉衍生物的盐的晶体 - Google Patents

喹唑啉衍生物的盐的晶体 Download PDF

Info

Publication number
CN109476634A
CN109476634A CN201780044063.9A CN201780044063A CN109476634A CN 109476634 A CN109476634 A CN 109476634A CN 201780044063 A CN201780044063 A CN 201780044063A CN 109476634 A CN109476634 A CN 109476634A
Authority
CN
China
Prior art keywords
crystallization
formula
compound
maleate
alcohol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN201780044063.9A
Other languages
English (en)
Other versions
CN109476634B (zh
Inventor
汤松
朱益忠
刘飞
周杰
陈智林
徐宏江
田心
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Capital Pharmaceutical Holdings (beijing) Co Ltd
Chia Tai Tianqing Pharmaceutical Group Co Ltd
Lianyungang Runzhong Pharmaceutical Co Ltd
Original Assignee
Chia Tai Tianqing Pharmaceutical Group Co Ltd
Lianyungang Runzhong Pharmaceutical Co Ltd
Shouyao Holdings Beijing Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chia Tai Tianqing Pharmaceutical Group Co Ltd, Lianyungang Runzhong Pharmaceutical Co Ltd, Shouyao Holdings Beijing Co Ltd filed Critical Chia Tai Tianqing Pharmaceutical Group Co Ltd
Priority to CN202110384280.0A priority Critical patent/CN113149960A/zh
Publication of CN109476634A publication Critical patent/CN109476634A/zh
Application granted granted Critical
Publication of CN109476634B publication Critical patent/CN109476634B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C51/00—Preparation of carboxylic acids or their salts, halides or anhydrides
    • C07C51/41—Preparation of salts of carboxylic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
    • C07C57/02—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms with only carbon-to-carbon double bonds as unsaturation
    • C07C57/13—Dicarboxylic acids
    • C07C57/145—Maleic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Abstract

本申请公开了式（I）化合物的马来酸盐的晶体、其制备方法、其结晶组合物、其药物组合物及它们在预防和***中的用途。

Description

PCT国内申请，说明书已公开。

Claims (13)

  1. PCT国内申请，权利要求书已公开。
CN201780044063.9A 2016-08-25 2017-08-24 喹唑啉衍生物的盐的晶体 Active CN109476634B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202110384280.0A CN113149960A (zh) 2016-08-25 2017-08-24 喹唑啉衍生物的盐的晶体

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN2016107302228 2016-08-25
CN201610730222 2016-08-25
PCT/CN2017/098798 WO2018036539A1 (zh) 2016-08-25 2017-08-24 喹唑啉衍生物的盐的晶体

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202110384280.0A Division CN113149960A (zh) 2016-08-25 2017-08-24 喹唑啉衍生物的盐的晶体

Publications (2)

Publication Number Publication Date
CN109476634A true CN109476634A (zh) 2019-03-15
CN109476634B CN109476634B (zh) 2021-04-02

Family

ID=61245459

Family Applications (2)

Application Number Title Priority Date Filing Date
CN202110384280.0A Pending CN113149960A (zh) 2016-08-25 2017-08-24 喹唑啉衍生物的盐的晶体
CN201780044063.9A Active CN109476634B (zh) 2016-08-25 2017-08-24 喹唑啉衍生物的盐的晶体

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CN202110384280.0A Pending CN113149960A (zh) 2016-08-25 2017-08-24 喹唑啉衍生物的盐的晶体

Country Status (6)

Country Link
US (1) US10858340B2 (zh)
EP (1) EP3505516B1 (zh)
JP (1) JP7036798B2 (zh)
CN (2) CN113149960A (zh)
RU (1) RU2019106531A (zh)
WO (1) WO2018036539A1 (zh)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114787151B (zh) * 2019-11-01 2024-04-16 正大天晴药业集团股份有限公司 喹唑啉衍生物或其盐、或其药物组合物的用途
CN114845723A (zh) * 2019-11-01 2022-08-02 正大天晴药业集团股份有限公司 包含喹唑啉衍生物或其盐的药物组合物

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CZ20022332A3 (cs) 2000-01-07 2003-01-15 Transform Pharmaceuticals, Inc. Sestava vzorků
TWI377944B (en) * 2007-06-05 2012-12-01 Hanmi Holdings Co Ltd Novel amide derivative for inhibiting the growth of cancer cells
CN104513229A (zh) 2013-09-28 2015-04-15 正大天晴药业集团股份有限公司 喹唑啉衍生物及其制备方法
RU2720810C2 (ru) * 2015-03-20 2020-05-13 Чиа Тай Тяньцин Фармасьютикал Груп Ко., Лтд. Соли производного хиназолина и способ их получения

Also Published As

Publication number Publication date
WO2018036539A1 (zh) 2018-03-01
CN113149960A (zh) 2021-07-23
EP3505516B1 (en) 2021-10-06
EP3505516A1 (en) 2019-07-03
RU2019106531A3 (zh) 2020-12-18
JP2019524857A (ja) 2019-09-05
JP7036798B2 (ja) 2022-03-15
RU2019106531A (ru) 2020-09-25
EP3505516A4 (en) 2020-01-22
US20190185453A1 (en) 2019-06-20
CN109476634B (zh) 2021-04-02
US10858340B2 (en) 2020-12-08

Similar Documents

Publication Publication Date Title
US9359370B2 (en) Icotinib hydrochloride, synthesis, crystalline forms, pharmaceutical compositions, and uses thereof
Hou et al. Design, synthesis, anti-tumor activity, and molecular modeling of quinazoline and pyrido [2, 3-d] pyrimidine derivatives targeting epidermal growth factor receptor
CN103965114B (zh) 氘代的苯基氨基嘧啶化合物以及包含该化合物的药物组合物
US10633364B2 (en) Crystals of quinazoline derivative and preparation method therefor
JP7323896B2 (ja) カゼインキナーゼ１ε阻害剤、医薬組成物及びその使用
Ding et al. Design, synthesis and biological evaluation of novel 4-aminoquinazolines as dual target inhibitors of EGFR-PI3Kα
CA2982881C (en) Preparation method for aromatic heterocyclic compound used as selective jak3 and/or jak1 kinase inhibitor and application of aromatic heterocyclic compound
Amin et al. Design, synthesis and molecular modeling studies of 2-styrylquinazoline derivatives as EGFR inhibitors and apoptosis inducers
CN101878203A (zh) 作为抗癌剂的新的4-(四唑-5-基)喹唑啉衍生物
CN109476634A (zh) 喹唑啉衍生物的盐的晶体
El-Deen et al. Design and synthesis of some novel pyridothienopyrimidine derivatives and their biological evaluation as antimicrobial and anticancer agents targeting EGFR enzyme
CN110016017A (zh) 一类嘧啶化合物的盐、多晶型物及其药物组合物、制备方法和应用
CN102584828B (zh) 吡咯烷[3，4-d]嘧啶衍生物、制备方法及其应用
CN107417626A (zh) 一种2‑氨基嘧啶类化合物的多晶型形式
US10689359B2 (en) Crystals of quinazoline derivative and preparation method therefor
CN109384788A (zh) 嘌呤系列衍生物及其制备方法和用途
WO2014071824A1 (zh) 4-氨基喹唑啉杂环化合物及其用途
Qin et al. Design, synthesis and biological evaluation of quinoxalin-2 (1H)-one derivatives as EGFR tyrosine kinase inhibitors
Lee et al. Structure–activity relationships of novel quinazoline derivatives with high selectivity for HER2 over EGFR
Malhotra et al. Novel amide analogues of quinazoline carboxylate display selective antiproliferative activity and potent EGFR inhibition
El-Saadi et al. Synthesis, docking and biological evaluation of 2, 4-disubstituted quinazolines with multi-target activities as anti-cancer and antimicrobial agents
US9512076B2 (en) Indirubin derivatives and uses thereof in treating chronic myelogenous leukemia
CN107827877A (zh) 二烷基氨基喹唑啉类化合物及其在制备抗肿瘤药物中的应用
Bano et al. Synthesis, single crystal X-ray diffraction, Hirshfeld surface and biological activity of quinolone derivatives
AU2014280709B2 (en) Polymorph forms of Icotinib maleate and uses thereof

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
TA01 Transfer of patent application right

Effective date of registration: 20190528

Address after: No. 369, Yuzhou South Road, Lianyungang, Jiangsu Province

Applicant after: Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Applicant after: Lianyungang Runzhong Pharmaceutical Co.,Ltd.

Applicant after: Capital Pharmaceutical Holdings (Beijing) Co., Ltd.

Address before: No. 369, Yuzhou South Road, Lianyungang, Jiangsu Province

Applicant before: Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Applicant before: Lianyungang Runzhong Pharmaceutical Co.,Ltd.

Applicant before: Beijing Centaurus Biopharma Technology Co., Ltd.

TA01 Transfer of patent application right
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1261832

Country of ref document: HK

CB02 Change of applicant information

Address after: No. 369, Yuzhou South Road, Lianyungang, Jiangsu Province

Applicant after: CHIA TAI TIANQING PHARMACEUTICAL GROUP Co.,Ltd.

Applicant after: LIANYUNGANG RUNZHONG PHARMACEUTICAL Co.,Ltd.

Applicant after: Capital Pharmaceutical Holdings (Beijing) Co.,Ltd.

Address before: No. 369, Yuzhou South Road, Lianyungang, Jiangsu Province

Applicant before: CHIA TAI TIANQING PHARMACEUTICAL GROUP Co.,Ltd.

Applicant before: LIANYUNGANG RUNZHONG PHARMACEUTICAL Co.,Ltd.

Applicant before: Shouyao holding (Beijing) Co.,Ltd.

CB02 Change of applicant information
GR01 Patent grant
GR01 Patent grant